Table 3.
Univariate and multivariate Cox proportional hazards analysis for progression-free survival and overall survival in EBVaGC
| Characteristics | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (≤ 57/> 57) | 0.64 (0.32–1.30) | 0.22 | 1.16 (0.60–2.23) | 0.66 | ||||
| Sex (Male/Female) | 0.80 (0.28–2.28) | 0.67 | 0.91 (0.32–2.58) | 0.86 | ||||
| Tumor size (cm, ≤ 4.5/> 4.5) | 2.70 (1.31–5.54) | 0.01 | 3.88 (1.86–8.09) | <0.001 | ||||
| TMN classification (I+ II/III+IV) | 27.8 (3.79–203.50) | 0.001 | 25.42 (3.46–186.83) | 0.001 | 25.46 (3.48–186.07) | 0.001 | 16.62 (2.25–122.71) | 0.01 |
| Tumor differentiation (poorly/Moderately) | 0.72 (0.36–1.46) | 0.37 | 0.65 (0.33–1.29) | 0.22 | ||||
| Lauren classification | 0.97 | 0.26 | ||||||
| Intestinal | 1 | Reference | 1 | Reference | ||||
| Diffuse | 1.15 (0.39–3.37) | 0.80 | 2.33 (0.84–6.44) | 0.10 | ||||
| Mixed | 1.02 (0.47–2.23) | 0.96 | 1.49 (0.62–3.56) | 0.37 | ||||
| Nervous invasion (Negative/Positive) | 2.97 (1.22–7.23) | 0.02 | 8.71 (2.07–36.58) | 0.003 | ||||
| Venous invasion (Negative/Positive) | 4.46 (1.93–10.32) | <0.001 | 5.62 (2.15–14.68) | <0.001 | ||||
| HER2 IHC score (0–1/2-3) | 1.06 (0.44–2.59) | 0.89 | 1.83 (0.88–3.81) | 0.11 | ||||
| PD-L1 expression (Negative/Positive) * | 0.36 (0.18–0.73) | 0.004 | 0.45 (0.22–0.92) | 0.03 | 0.15 (0.07-.034) | <0.001 | 0.17 (0.06–0.43) | < 0.001 |
Abbreviations: EBVaGC, Epstein-Barr virus associated gastric cancer; HR, hazard ratio; TNM, tumor node metastasis; PD-L1, programmed cell death protein ligand 1; IHC, immunohistochemistry.
* PD-L1 positive expression is defined as CPS score ≥ 1.